Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, and Tempus, a technology company leading the adoption of AI to advance precision ...

Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement ...

ASCO Genitourinary Cancers Symposium approaches, several highly anticipated studies are set to shape the future of treatment ...

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers Will Be Presented at the 2025 ASCO GU Symposium.

A recent update of this original risk stratification scheme addressed not only recurrence, but also prostate-cancer-specific mortality, in an expanded multicenter database of over 7,000 patients ...

Results of a study led by the Vall d'Hebron Institute of Oncology (VHIO) support the feasibility of using RAD51 testing to ...

Functional assays that can detect dynamic changes in HRR capacity could also support patient stratification strategies and help ... or metastatic biopsies from 187 patients with advanced prostate ...

Untreated prostate cancer can sometimes cause erectile dysfunction (ED). However, ED is more commonly associated with ...

An integrated strategy for the prevention, support and treatment of prostate cancer was launched today. The plan, which was ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...